ArticleCancer management and research2026
Identifying of Ubiquitin-Fold Modifier 1 as a Potential Prognostic Biomarker for Unresectable Pancreatic Cancer by Proteomics Analysis.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis for unresectable pancreatic cancer remains poor, with limited biomarkers available to predict treatment response and survival. This study aimed to identify novel protein biomarkers associated with therapeutic resistance in this disease. Methods: We performed proteomic analysis by Data-Independent Acquisition mass spectrometry on FFPE tissues from 10 patients with unresectable pancreatic cancer, comparing treatment-sensitive and treatment-resistant groups. Differentially expressed proteins were identified, and the candidate was validated by immunohistochemistry in an independent cohort of 91 patients. Survival analysis and Cox regression were used to evaluate the prognostic significance of protein expression. Results: In this study, proteomic analysis revealed Ubiquitin-fold modifier 1 (UFM1) as a significantly upregulated protein in treatment-resistant. High UFM1 expression was significantly associated with advanced TNM stage (P < 0.05) and poorer treatment response (P = 0.016). Patients with high UFM1 expression had significantly shorter median PFS (6.5 vs 12.0 months; HR = 0.335, 95% CI: 0.209-0.537, P < 0.001) and OS (10.4 vs 20.5 months; HR = 0.298, 95% CI: 0.184-0.484, P < 0.001) compared to those with low expression. Multivariate Cox regression confirmed UFM1 as an independent prognostic factor for both PFS (HR = 0.343, P < 0.001) and OS (HR = 0.304, P < 0.001). Conclusion: UFM1 is a promising prognostic biomarker for unresectable pancreatic cancer, with high expression indicating aggressive disease and inferior outcomes. These findings support its potential utility in risk stratification and treatment personalization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.